GRP-THINK AT THE BBB
How anti-GRP78 antibodies could help therapeutic mAbs get through the BBB
Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development.
The inability to concentrate therapeutic antibodies in the brain has long dogged drug makers, particularly in Alzheimer’s disease, where insufficient levels of anti-β amyloid antibodies is proposed as one cause of their failure to clear senile plaques...
BCIQ Company Profiles